Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ritlecitinib 50 mg and 100 mg in adolescents and adults with alopecia areata
2024-519370-40-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of ritlecitinib tosilate in alopecia areata (3 arms), sponsored by Pfizer. Primary endpoints: SALT response at Week 24, Treatment-emergent adverse events and 1 more. Planned start Jul 2025; status: authorised.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2024-519370-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519370-40-00.